Interesting Presentation of Acute Intravenous Methotrexate Leukoencephalopathy

Tarek El-Halabi, Sidonie Ibrikji and Johnny Salameh*
Department of Neurology, American University of Beirut Medical Center, Lebanon

Abstract
Acute toxic leukoencephalopathy should be considered in a patient presenting with new onset neurologic deficit with known exposure to a toxin that has been described to injure the white matter. Methotrexate and 5-Fluorouracil are the most commonly reported offenders chemotherapeutic drugs. The below reported case is interesting as it is the first reported case of acute focal neurological deficit, followed by improvement few hours later; with minimal residual deficits on neurologic exam, along with acute changes on MRI, being diffuse white matter lesions without any restriction or enhancement, in a patient without exposure to intrathecal methotrexate. It confirms that Methotrexate induced leukoencephalopathy should be high on our differential, even when only administered intravenously.

Keywords: Chemotherapy; Acute toxic leukoencephalopathy; Intravenous methotrexate

Introduction
Toxic leukoencephalopathy is important to identify early on as it is potentially reversible if the offending agent is withdrawn before the onset of irreversible damage [1]. Although multiple chemotherapeutic drugs are used in addition to methotrexate, the acute neurotoxicity reported in cancer patients are mostly attributed to methotrexate. Its incidence ranges from 3% to 10%, and varies with the dosage, route of administration and frequency of methotrexate given. Risk factors being high dose treatment, intrathecal route, young age and association with cranial irradiation [2]. This can be explained based on the metabolic derangement from folate deficiency and homocysteine elevation induced by cumulative effects of repeated administration of methotrexate, both intravenously and intrathecally, which might result in small vessel vasculopathy or indirect excitotoxic effects [2]. The clinical presentation can vary from headache, dizziness and depression when the toxic agent is taken in low doses to more severe symptoms like confusion, seizures, ischemic attacks, posterior reversible encephalopathy syndrome, cerebellar dysfunction and myopathy [1].

Brain Magnetic Resonance Imaging (MRI) plays a crucial role in diagnosis, as it excludes the main differential diagnosis including ischemic events, malignancies, and infections. The typical findings in methotrexate induced leukoencephalopathy include nonspecific diffuse white matter T2/ Fluid-attenuated inversion recovery (FLAIR) changes [3]. However, it can also present as focal area of restricted diffusion in deep periventricular white matter which is reversible radiologically on Diffusion Weighted (DW) MRI and corresponding Apparent Diffusion Coefficient (ADC) map, in parallel with clinical outcome [3].

Case Report
A 27-year-old right handed lady, known to have osteosarcoma involving the Right ulna diagnosed 8 months prior to presentation s/p resection and systemic chemotherapy (cisplatin, methotrexate 12 grams, doxorubicin), with the last session being few days prior to her presentation; where the patient experienced acute right lower extremity weakness upon awakening, not being able to move her leg against gravity. This lasted more than 4 hours, after which improvement was noted, but was still not back to her baseline. Review of system was negative for other focal deficits, seizure-like activity, altered level of consciousness, palpitations, or chest pain.

On physical examination, patient was afebrile, with a blood pressure of 140/80 mmHg and a heart rate of 70 b/min. Neurologic examination revealed no evidence of cranial nerve abnormalities, her right upper extremity testing was limited by the previous surgery involving the right ulna but there was no difference in the arm from her baseline. Her right lower extremity had a 4/5 motor power, mainly involving hip flexion. Rest of muscles had a 5/5 power. No peripheral or cortical sensory deficits. Deep tendon reflexes were symmetric 1+ in both arms, no reflexes elicited in both lower extremities and absent Babinski sign bilaterally. There were no abnormal cerebellar signs.

Patient underwent Brain MRI that compared to a previous image done few months prior showed new bilateral and asymmetric (left more severe than right), confluent periventricular white matter, centrum semi-ovale high T2 signal abnormalities, sparring the U-fibers (Figure 1). They were not typical of multiple sclerosis, infectious process, or cancer.

Lumbar puncture was performed, and cerebrospinal fluid studies showed 2 white blood cells with a protein of 0.35 g/L. Cytology was negative for malignant cells, and infectious profile for viruses, bacteria and fungi, was completely negative. John Cunningham (JC) virus titers were negative as well.

Discussion
Acute toxic leukoencephalopathy should be considered in a patient presenting with new onset neurologic deficit with known exposure to a toxin that has been described to injure the white matter [2]. Methotrexate and 5-Fluorouracil are the most commonly reported offenders chemotherapeutic drugs [2]. The patient reported in this case was on methotrexate IV , which was believed to be the cause of her symptoms.

*Corresponding author: Johnny Salameh, Department of Neurology, American University of Beirut Medical Center, Cairo Street, Hamra, Beirut, Lebanon, Tel: 961-1350000; E-mail: johnnysalameh@hotmail.com

Received September 03, 2018; Accepted September 24, 2018; Published September 29, 2018


Copyright: © 2018 El-Halabi T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conclusion

This case is interesting as it is the first reported case of acute focal neurological deficit, followed by improvement few hours later; with minimal residual deficits on neurologic exam, along with acute changes on MRI, being diffuse white matter lesions without any restriction or enhancement, in a patient without exposure to intrathecal methotrexate. It confirms that Methotrexate induced leukoencephalopathy should be high on our differential, even when only administered intravenously.

References

